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ABSTRACT
The objectives of this program were to establish, in Newfoundland,
the recently described method for making monoclonal antibodies by cell
fusion, to explore various aspects of the technique and to attempt to
produce lymphocyte hybridomas secreting monoclonal antibodies against
human erythrocyte antigens.
Fusion, with the aid of polyethylene glycol, of spleen cells from
an immunized mouse with mouse plasmacytoma cells, may result in formation
of hybrid cells. Such hybrids, which contain a B lymphocyte nucleus from
the spleen cells, may make monoclonal antibody.
Tests showed the plasmacytoma cells grew well in medium RPMI 1640
with 10% fetal calf serum from a concentration of 2.5 x 10 4 to 4 x 105
cells per ml. but viability declined rapidly if cultured longer.
Polyethylene glycol was found to be toxic to these cells but a suitable
concentration was found which allowed both cell fusion and survival of the
resulting hybrids. Preliminary testing of the mouse response to red cells
(RBC) of various species showed that the standard Jerne plaque technique
gave good results with sheep RBC but no plaques with human RBC, even though
serum antibody titres were satisfactory. Techniques were later established
for detecti6n, in culture fluid, of mouse immunoglobulin (inhibition of the
antiglobulin test) and of specific anti-RBC antibody (agglutination).
After 35 fusions and various modifications, the method began to
produce hybridomas. Altogether in a series of seven successful fusions
152 colonies were produced with 82 colonies secreting mouse immunoglobulin
and 4 of those secreting anti-human RBC antibody.
Of nine species of red cells tested, the only ones to be agglutinated
by the four culture supernatants were human RBC. Red cell samples from
87 unrelated humans were screened and all were agglutinated by each of
the four culture supernatants. Using 2-mercaptoethanol all four
antibodies behaved as if they were Ig M. It was concluded that these
monoclonal antibodies were species specific and not detecting alleles.
It is evident from these and other published studies that monoclonal
antibodies with allelic specificity may be less easy to obtain than
expected.
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REVIEW OF PERTINENT LITERATURE
INTRODUCTION
The development of the cell fusion technique came about through
contributions from several fields notably genetics in which nuclear
control of cells was under investigation. Shortly thereafter the need
for a reproducible antibody reagent as an immunological tool was filled
by adapting the cell fusion technique to the mouse B lymphocyte and a
mouse myeloma cell line. This produced a hybridoma cell line which
secretes monoclonal antibody.
Studies of the antibody repertoire of inbred mice indicate a
range of between 1 - 5 x 10 7 uniquely different antibody producing
cells. la, lb Between 1,000 and 8,000 different antibodies appear to be able
to recognize a single hapten. Yet when the conventional response to
antigen is analysed only 5-10 antibody species are seen, representing
probably a random sample of the antibody repertoire. la Considering the
circumstances the difficulty in reproducing reagents against a particular
antigen becomes clear. For instance when a mouse is immunized with
xenogeneic cells, between 10 and 100 separate molecules will be
recognized. Against each antigenic determinant the mouse may produce
a number of distinctly different antibodies. Thus thousands of different
antibodies may be produced in response to immunization. The resulting
antiserum may be absorbed with appropriate cells, or the mouse may be
immunized with allogeneic cel Ls in which case the heterogeneity will be
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decreased. Even under these conditions the sera have three major
drawbacks: (1) though specific the serum is still heterogeneous;
(2) amount of sera is strictly limited; (3) the particular antiserum
is not reproducible even when obtained from the same mouse.
The possibility of producing a monoclonal antibody of high titre,
available in large quantities and on a continuing basis has become a
fortunate reality through immortalization of antibody producing cells
by fusion with an established plasmacytoma line.
Historical Aspects of Cell Fusion
Multinucleate cells: spontaneous fusion and virally induced fusion.
Multinucleate cells in vertebrates were first described over a
hundred years ago by Muller2 who observed them in tumors. Virchow3
noted their presence in a variety of normal tissues and both inflammatory
and neoplastic lesions. Multinucleate cells in pathological lesions
were described by many researchers in the last century. It is very
probable that some of the inflammatory lesions in which multinucleate
cells were observed in the last century were caused by viruses although
the viral aetiology of these conditions was not recognized until much
later. The earliest reports of multinucleate cells in lesions which
can be certainly identified as of viral origin appear to be those
of Luq i.nbuhL (1873) 4, Unna (1896) 5, and Warthin (1931) 6, who described
such cells at the periphery of smallpox pustules, skin lesions of
chicken pox, and the tonsils of patients with measles, respectively.
Following the introduc~ion of tissue culture methods by Harrison 7
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in 1907., numerous observations were made on cell fusions in cultures of
animal tissues. By the 1950s many examples of virally induced fusions
in tissue culture began to appear in scientific literature8,9,10,11,12
That fusion could occur spontaneously as an event of low frequency in
cultures of discrete cells was first recognized by Barski, Sorieul and
cornefert1 3 in 1960 who isolated a hybrid line from a mixed culture of
two mouse cell lines. Many hybrid lines have since been isolated.
Where the formation of a hybrid depends on spontaneous fusion the number
of hybrid cells formed is small and varies from one system to another.
However Okada (1958) 14 demonstrated that animal tumor cells in suspension
could be rapidly fused together to form multinucleate giant cells by high
concentrations of HVJ virus (also known as Sendai virus), a member of the
para influenza group. The next step in cell fusion was undertaken in a
collaborative effort between Harris and Watkins (1965) 15 using the
observations of Okada. In their experiment Harris and Watkins used
inactivated Sendai virus as fusagen demonstrating that this could promote
fusion not only between similar cells but also between cells of different
species such as avian erythroblasts and human cultured cells resulting in
viable hybrids. This development provided the tool for investigation into
the control of genetic information within the cell through nucleo-cytoplasmic
relationships16. Of equal importance, interspecies hybrids between
human and mouse cells contributed information which permitted human
gene products to be assigned to particular chromosomes. At this time
the immunological value of this tool had not yet been realized.
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The viability of hybrid cells may be jeopardized by infection with
the viral fusagen, therefore the virus is killed with ultra violet light
before being used as the fusing agent. Ultra violet light inactivated
Sendai virus has thus provided a general method for fusing together
differentiated and undifferentiated cells from various species and even
different orders of vertebrates1 7. This fusagen has now been extensively
used.
Chemically induced fusion
Recently it has been shown that polyethylene glycol (PEG) can be
used to induce fusion between animal cells18, 19. Qualitatively, fusion
using PEG is indistinguishable from that induced by Sendai virus but
due to ease in preparation and stability of PEG fusagen as well as
elimination of the danger of incorporation of the viral genome of the
inactivated Sendai virus20a into the fused cell, the chemical fusagen
PEG has replaced Sendai virus. It is worth noting that Sendai virus is not
very effective in bringing about fusion of mouse lymphocytes 20b whereas
PEG works very well.
Early Fusion Experiments
By the early 1970s hybridization studies had supplied valuable
information in many biological systems but offered little promise for
immunologists. Nonetheless, 'the plasmacytoma induced in mice and
adapted for growth in tissue culture, was often a partner in fusion
experiments. In 1973 Cotton and Milstein fused two such immunoglobulin
producing cells and found that the resulting hybrid cells secreted
immunoglobulin of both parental types. 21
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Shortly thereafter Kohler and Milstein (1975) 22 undertook fusion
of normal lymphocytes with cells of a myeloma line. The spleen, rich
in lymphocytes, was used as the source of one parental line in the
fusion. Following immunization of an animal, proliferation of
lymphocytes p roduce d antibody against the immunogen; in this case
sheep erythrocytes. Remarkable results followed fusion of the lymphocytes
with myeloma cells. The use of Littlefields selective medium23
subsequent to exposure to the fusagen allowed survival of only those
cells which had fused. In this experiment growth of cells in selective
medium was exhibited in 4 out of 10 petri dishes containing Sendai
virus treated cells. These were taken as independent hybrid lines
probably each derived from a single fusion event. Those in which anti-
sheep erythrocyte activity was evident were subcultured and almost all
the clones of the derived purified line proved capable of lysing sheep
erythrocytes. These hybrids of normal activated lymphocytes and the
tumor cell MOPC 21 produced both anti sheep erythrocyte antibody and
MOPC 21 myeloma protein.
The possibilities extended by this crucial experiment are immense:
a plasma cell demonstrating a particular specificity of antibody can now
be perpetuated through cell fusion with a continuous cell line and
production of that antibody in unlimited quantity has now become possible.
Myeloma variants
Sublines and variants of the myeloma were developed. 24 Studies of
myeloma cells have shown that variants which lose the capacity to secrete
immunoglobulin arise spontaneously with a frequency of the order of
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10-3 - 10-4 per cell generation25,26 Through appropriate detection
and isolation techniques, rare variant myeloma cells secreting specific
macromolecules can be obtained2 7. The cell line used in Kohler and
Milstein I S notable experiment, P3-X63-Ag8 secretes the MOPC-21 protein
an immunoglobulin of the class y, K. In a later experiment by them28
a non-secreting variant of the MOPC-21 myeloma was used: NS1/l-Ag4-1
which does not express heavy chain immunoglobulin.
Subpopulations
Al though the fusion of mouse myeloma cells to antibody forming
spleen cells has already been effective in producing monoclonal anti-
bodies, many of the technical problems have not been solved and some
of the fundamental questions have not been answered. It is not yet
clear whether fusion occurs in a specific subpopulation of cells
within the myeloma line and of lymphocytes within the stimulated spleen,
although it is clear that heterogeneity wi thin these cells in terms of
cell cycle and differentiation states exists, indicating a potential
for such restrictions. It seems likely that the activated B lymphocyte
in its blast stage is the preferred partner for fusion with the myeloma
cell, since small resting B cells could not be fused to yield hybrid
lines. 29
Biological Action of Polyethylene Glycol (PEG)
PEG efficiently fuses mammalian cells over a wide range of
molecular weights. Nonetheless, the exposure time and concentration
of PEG are critical to the viability of the fused cells. Studies of
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optimal conditions have been carried out with various molecular weights
of PEG, concentration of and exposure time to PEG. 30 Addition of
dimethyl sulfoxide to fusagen was found in this study to dramatically
increase the production of viable multinucleated cells over a range
of concentrations of PEG.
Membrane changes 31
Increasing fluidity of cell membranes is common to treatment
with PEG, Sendai virus and lysolecithin. Extensive fusion of cultures
occurs 2-4 hours following exposure to PEG. At this time coalescence
of the membranes has occurred leading to incorporation of 2 or more
nuclei in the resulting multinucleate cell. Although multinucleate
cells produced by cell fusion may under favorable conditions remain
alive for several weeks, their continued reproduction is conditional
upon the formation of daughter cells that contain a single nucleus.
When cells contain more than one nucleus irregular and abortive mitosis
becomes more common. In cells where asynchrony of DNA synthesis
persists the incidence of mitosis is greatly reduced; when it does
occur chromosomes of the lagging nucleus may undergo disruption
(chromosome pulverization) and ensuing maldistribution of chromosomes
may be lethal.
Nuclear rearrangement31
If the fused cell enters mitosis, the nuclear envelopes disappear
and the chromosomes become condensed. Very little is known about spindle
formation and the mechanism of chromosome distribution to hybrid daughter
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cells. Many fused cells abort at this stage or within the next few
generations. In the small number that form daughter nuclei, the process
may be achieved in a variety of ways but all of them mediated by the
fusion of the individual nuclei in the multinucleated cell. This fusion
takes place at mitosis. In binucleate cells synchronous mitosis of the
two nuclei is commonly associated with the formation of a single spindle.
All the chromosomes become aligned along a single metaphase plate, and
division of the cell produces two mononucleate daughter cells that
contain within one nucleus the chromosomes from both parental cells.
Other forms of mitosis are also seen in which there is a less equal
representation of parental chromosomes.
For the hybrid to evolve into an established cell line, at least
one parent has to contribute a capacity to proliferate. The genotype
of the hybrid depends in a striking manner on the species relatedness
of the parents. Intraspecific hybrids retain more than 90% of the sum
of parental chromosomes and remain remarkably stable over long periods.
Selective Medium
Folic acid antagonists
Folic acid is a compound made up of the pteridine nucleus, p-
aminobenzoic acid, and glutamic acid. The folic acid co-enzymes are
specifically concerned with biochemical reactions involving the transfer
of the single carbon moiety in the folic acid cycle and participate in
synthesis of purines, thymine and methyl groups. Maximal inhibitory
action is obtained when an amino group is substituted for the hydroxy
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group on position 4 on the pteridine nucleus. 32 Thus aminopterin
(4-amino folic acid) is the most potent folic acid inhibitor yet
discovered. Another antagonist is amethopterin (4-amino-10-methylfolic
acid; metho trexate). The interference of the antimetabolites occurs
in the reduction of folic acid to the tetrahydro compound. Reduction
is a necessary preliminary to the carriage of the one carbon moiety.
Thus folic acid antagonists are extremely potent competitive inhibitors
of the reductase reaction H2 folate ->- H4 folate.
In tissue culture it has been found that aminopterin blocks the
synthesis of nucleic acids, presumably by preventing the reduction of
folic acid to the tetrahydro derivative the form that is a major donor
to the formyl (singly carbon) to the purine ring. The participation of
the folic acid co-enzymes in reactions leading to synthesis of purines
and methylated pyrimidines of DNA emphasize the fundamental role of
folic acid in growth and reproduction of cells. Such inhibited cells
fail to complete their mitoses; they do not progress from metaphase to
anaphase because of failure in the synthesis of nucleoprotein - a
synthesis which is essential to chromosome reduplication.
Purine salvage pathway
Some tissues within mammalian organisms, are dependent upon exogenous
purines or purine ribonucleotides32,33. The salvage of these preformed
purine compounds occurs by phosphoribosylation of free purine bases by
specific enzymes requiring diphospho ribose phosphate (PPribose-P) as
the ribose phosphate donor. The enzyme capable of phosphoribosylating
hypoxanthine and guanine with PPribose-P to yield inosine monophosphate
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(IMP) and guanine mono phosphate (GMP) respectively is hypoxanthine
guanine phosphoribosyltransferase (HGPRT). Mammalian cells also have
active salvage pathways for converting the pyrimidine nucleoside
thymidine to its nucleotide. The enzyme involved is thymidine kinase
(TK).
In the event that folic acid synthesis is blocked through administration
of the antimetabolite aminopterin, addition of exogenous hypoxanthine
and thymidine will bypass the blockade. The conversion of these bases
progresses to DNA synthesis through a series of steps the first of which
is catalysed by the enzymes HGPRT or TK. Thus cells with normal levels
of HGPRT can circumvent the effects of the folate antagonist amino-
pterin if sufficient amounts of exogenous hypoxanthine are available,
whereas those cells with a deficiency of this enzyme will not survive
in a medium supplemented with aminopterin even when exogenous hypo-
xanthine is present.
The plasmacytoma line is a deliberately derived variant of the
original cell lines producing HGPRT and is one in which the enzyme HGPRT
is lacking. Therefore in tissue culture medium containing HAT (hypoxanthine,
aminopterin, thymidine) these cells will stop dividing and will die. The
selective medium developed by Littlefield2 3 utilizes this characteristic
to kill off the unfused myeloma cells in the fusion mixture.
Development of Plasmacytoma Lines
The induction of plasma cell tumors has been employed for well
over twenty years. It is a remarkable and fortunate experimental fact
that plasma cell tumors can be produced in unlimited numbers in the
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highly inbred BALB/c strain of mice by relatively simple procedures
such as the intraperitoneal injection of mineral oil. 34 The basis
for formation of tumor cells in response to mineral oil injection is
not fully understood, but a number of factors have been described;
foremost amongst these is the unique genetic susceptibility of the
inbred BALB/c strain of mice. A second factor of interest is the
abnormal peritoneal environment created in treated BALB/c mice. In
most cases of an ascites tumor bearing mouse, the tumor cells character-
istically produce a single type of immunoglobulin as all tumor cells
are derived from a single highly proliferative malignant myeloma cell,
hence the term monoclonal antibody is used to describe its secreted
product. While the great majority of such plasmacytomas are mono-
clonal when assessed by immunological means they nevertheless
originate within normal cells. The abnormal proliferative capacity
probably develops only in a single cell but with this proliferative
advantage soon make up the bulk of cells within the ascitic fluid.
Plasma cell tumors have been most useful in providing a source
for large quantities of homogeneous immunoglobulin, since most of the
tumors are relatively easy to transplant in syngenic hosts. These
transplantable tumors attain large size, often more than one third
of the body weight of the affected mouse. Large quantities of
immunoglobulin can be obtained from the serum and the ascitic fluid
or light chains from the urine of the mouse. Stability of the plasmacytoma
is good and it maintains production of the characteristic immunoglobulin
over many generations. The oldest immunoglobulin producing tumor X5563
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has been in nearly continuous passage since 1957 and still produces
the same immunoglobulin. 35
H.A.T. sensitivity
Subclones arising from low level spontaneous mutation will not
proliferate faster than other cells in the absence of selective
pressure. Applying such pressures allows one to select subclones that
exhibit interesting and useful variations. There is a high correlation
between resistance to the purine analogue 8-azaguanine and the absence
of the enzyme HGPRT. 36 Therefore the HGPRT defective myeloma cells can
be selected for through resistance to 8-azaguanine in a single step
selection. Cloning myeloma cells in 3 ~g/ml 8-azaguanine results in
survival of resistant clones only, which will subsequently not survive
in HAT medium. 36 Similar selection procedures can be used to isolate
variant myeloma 'c e l l s defective for the enzyme thymidine kinase (TK).
Thymidine kinase utilizes exogenous thymidine to overcome the central
aminopterin block in much the same way that HGPRT utilizes hypoxanthine. 32,33
Such variants as the TK- myeloma are selected for by their resistance to
30 ~g/ml of the pyrimidine antagonist 5' -bromodeoxyuridine (BUdR) 37.
These particular traits are stable in the absence of selective pressure.
The significance of the presence of drug sensitivity synonymous
with a particular cell is great, for administration of the drug can
be used to eliminate this cell selectively. Selection for the genetic
markers can be employed in various cell types not restricted to the
plasmacytoma.
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Further selection
The occurrence of spontaneous mutation is a low frequency event
in cell cultures. In the absence of selective pressures, such variants
will not normally be obvious, yet subcLon.i.nq and characterization of
these s ubc Lones unveils this clonal diversification. The spontaneous
mutation of plasmacytomas in tissue culture was examined by Coffino and
Scharff (1968) 38 leading to their isolation of nonsecreting, nonproducing
variants. SubcLories isolated from the culture were examined by iso-
electric focusing of labeled products. Varients showing the loss of
a heavy chain were revealed in the IEF screening by the absence of
immunoglobulin bands.
P3-NSI-1-Ag4-1
The myeloma cell line NSI-1 was developed for use in fusion
experiments by Kohler and Mi1stein. 39 The myeloma cell line is of
BLAB/c origin and does not grow in selective medium (HAT23). It does
not synthesize the heavy (y1) chain, but does produce light (K) chain
which, however, is not secreted. A variant line P3-NSI-1-Ag4-1 (short
name NS-1) resistant to 20 llg/m1 of 8-azaguainine, dying in HAT medium,
was isolated and used for fusion by Kohler and Milstein.
The NS-1 myeloma line was obtained through Dr. Elizabeth Simpson
of the Clinical Research Center in Harrow U. K. and is from the original
line of Dr. C. Milstein. The NS-1 myeloma cell was used in my early
fusion experiments.
The myeloma line MOPC 315.43, used in the hybridization experiments
reported on in much of this study was obtained through Dr. K.C. Lee
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from Dr. T. Mosmann both of the Department of Immunology of the
University of Alberta. MOPC 315 is a plasmacytoma derived from a tumor
induced in the BALB/c mouse and which secretes immunoglobulin with a
heavy and A light chains. Isolation of subclones subsequently produced
subline 315.26 which synthesizes no a heavy chain protein but does
make and secrete A light chains. This subline was grown in 6-thio-
guanine (6-TG, 1 ~g/ml) to select a resistant nutant.
Clone 315.32 was isolated and found to be able to grow in the
presence of 6-TG (10 ~g/ml) but unable to grow in HAT medium2 3 suggesting
that the enzyme function of hypoxanthine phosphorysosyltransferase
(HGPRT) had been lost. All subsequent variants derived from 315.32
remained 6-TG resistant, HAT sensitive.
Subclone 315.34 was derived in which the A chain is synthesized but
not secreted. The added trait of ouabain resistance was selected for
by growth in medium containing ouabain. 43 Subclone 315.43 developed
in a medium supplemented with ouabain at a level cytotoxic to the wild
type population. This variant remained HAT sensitive and produced but
did not secrete light immunoglobulin chains. The nonsecretion is due to
a structural mutation of the immunoglobulin chain; therefore when
hybridized with a lymphocyte this chain is still not secreted - no
contaminating light chain is found in the hybrid I s product. The
resul ting subclone developed for use in the lymphocyte hybridoma
experiments was a nonsecreting plasmacytoma resistant to ouabain and
sensitive to HAT.
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Gently mix the suspension of myeloma cells and under sterile
conditions transfer 0.1 ml to a 3 ml test tube. Add 0.1 ml of a 0.2 %
trypan blue solution in P.B.S. to test tube. Count must be done
between 2 and 10 minutes following trypan blue addition. Agitate the
tube to mix solutions and place a small drop under the cover slip of
the hemocytometer and focus under low power of the microscope. Count
the total number of cells and the stained cells in each of the four
corner groups of 16 large squares of the hemocytometer grid. There should
be 10-50 cells total (cell density 5 x 10 4 - 2.5 x 10 5) and 5-10 % stained
cells is acceptable (non viable cells). In the case of spleen cells, the
cells must first be diluted 1: 100 PBS, and in converting the count to
cells/ml, dilution factor is 100 and conversion factor is 2.5 x 10 5.
Conversion of Count to Cells/ml
area counted
depth
dilution factor
conversion factor
x .1 rom
x 5 x 10 3
Thus a cell count of 28 is converted to 28 x 5 x 10 3 = 1. 4 x 10 5
cells/m1.
III Freezing Myeloma Cells and Hybrid Cells
Materials and Equipment
Freezing machine
Ce n t r i f ug e
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Nunc tubes
DMSO 20% in RPMI - 15% FCS
RPMI - 15% FCS
Set freezing machine on 4°C. Centrifuge cell suspension at 900 g
for 2 minutes. Resuspend cell button in 10 ml RPMI - 15% FCS at 1 x 10 6
cells/ml. Add 10 ml of cell suspension to 10 ml DMSO solution. Mix
and put 1 ml of mixture into 20 Nunc tubes. Put vials into freezing
machine and set to freeze to -30°C. Leave for 2-3 hours. Transfer
vials to liquid nitrogen.
Thawing Cells
Nunc tubes containing frozen cells
15 ml screw cap 't e s t tubes
RPMI - 15% FCS ice cold
RPMI - 15% FCS room temperature
Take nunc tubes from liquid nitrogen and thaw in 37° bath.
last ice crystal melts put cells on ice. Transfer the 1 ml cell
suspension into 10 ml ice cold medium. Centrifuge at 900 g, for 2-4
minutes to wash cells. Remove supernatant and resuspend cells in
medium at room temperature. Centrifuge cells at 900 g for 2-4 minutes.
Remove supernatant and resuspend cells in 10 ml of medium 15% FCS -
cell density should be - 4 x 10 5/ml. Courrt. :cells and adjust density
if necessary. Put cells in culture vessel with loose cap in CO2
incubator at 37°C.
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IV 1 0 Immunization of Mice
~
Antigen: washed human RBC, 20% v/v in PBS in 10 ml test tube
10 ml syringe
23 gauge needle
BALB/c mouse
Method
Priming of BALB/c mouse prior to fusion: IgM antibody is desirable.
Inject Lp. 0.2 ml of the 20% RBC suspension into an adult BALB/c
mouse. Hybridization of the mouse's spleen cells with myeloma cells
is performed 4 days later.
Preparation of Cell Suspensions from Mouse Spleen Cells
Materials
BALBIc adult mouse
2 pairs sterile sissors
3 pairs sterile forceps
Cork board
Pins
EtOH 70% in water
Petridish (sterile)
Serum free RPMI (RPMI (0» chilled, 1% F/s
2 x 21 gauge needles (sterile) l~" long
2 x 5 ml syringes
10 ml pipette (sterile)
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Hemocytometer
Test tube
WBC diluting fluid
White blood cell diluting fluid: working solution
glacial acetic acid
H20
Methylene blue
2.0 ml
98. a ml
1 drop (1 drop'" 25 )1£)
Method
Immunologically primed mice are anesthetized or killed by cervical
dislocation. Pin mouse on cork board. Wash abdominal area generously
with 70% ethanol. Using 1 set of sterile sissors with the help of
forceps, cut through skin longitudinally on abdomen ensuring not to
pierce peritoneum. Pull back flap of skin on your right hand side of
2" incision and pin to cork board. With second set of sterile instruments
cut peritoneum longitudinally ensuring not to touch skin of mouse with
sterile instruments. Holding the flap of skin on your right hand side
the spleen is visible. With the third pair of sterile forceps grip
the adhering connective tissue beneath the spleen and lift out the
spleen. Transfer spleen to petridish containing 5-10 ml of chilled
RPMI (0) . Remove any connective tissue from spleen. Attach 21 g needle
to syringes. Partially withdraw needle from cover and bend it against
the cover to put a 90° bend in the needle. Using 2 such needles cells
can be squeezed from the spleen like a toothpaste tube. Discard outer
cover of spleen. Draw cell suspension up and down in 10 ml pipette to
break up lumps. Allow large lumps to settle for 1 minute and put 1 or
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2 drops of cell suspension in test tube for counting. Using a RBC
diluting pipette draw cell suspension up to the 0.5 mark. Draw WEC
diluting fluid up to 100 mark. Mix well by inverting several times.
Discard first 3 drops from pipette. Fill chamber of hemocytometer and
count area of the 4 corner groups of 16 large squares on the hemo-
cytometer grid. Convezs i.on factor for count to cells per ml is 5 x 10 7
Resuspend spleen cells in petri dish and allow large lumps to settle
for 1 minute. Being careful not to draw up large lumps, remove the
required volume of spleen cell suspension with a 10 ml pipette.
Preselection of Mouse Spleen Cells using poly-L-lysine
The rationale for preselection of mouse spleen cells is the know-
ledge that cells which are capable of binding antigen also secrete
antibody to the same antigen. Thus the mouse lymphocytes should
recognize and adhere to erythrocytes posessing the particular antigenic
determinant against which they produce antibody. 44
In negative selection the lymphocytes recognize species determinants
and numerous blood group determinants on erythrocyte "type 2". Only
lymphocytes which are not specific for any of these antigenic determinants
are nonadherent and may be easily poured off the plate coated with
type 2 erythrocytes.
These nonadherent cells are then positively selected. In positive
selection the remaining lymphocytes recognize determinants for blood
groups present only on erythrocyte "type 1" that are not common to
erythrocyte "type 2". Pour off and dispose of nonadherent lymphocytes.
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Thus the adherent lymphocytes are specific for RBC groups present on
erythrocyte "type 1" which are not present on erythrocyte "type 2".
The coated plate with adherent lymphocytes is treated with white cell
diluting fluid to lyse erythrocytes and the remaining lymphocytes are
retained for fusion.
Reagents
White Blood cell diluting fluid (WCDF)
poly-L-lysine: Stock solution 1 mglml (PLL)
Make up 0.2 ml/S ml PBS
PBS
2 ml 1% freshly washed RBC in PBS of type 1
2 ml 1% freshly washed RBC in PBS of type 2
Equipment
2 plastic Falcon petri dishes
100 ml beaker 15 ml conical centrifuge tube
Centrifuge
Method
Pour 2 ml of diluted PLL into each of 2 petri dishes and leave
at RTo for 15'. Pour off PLL and thoroughly rinse petri dishes with
PBS. Pour 2 ml of 1 % freshly washed RBC type 1(2) into petri dishes
#1 (2) and allow to settle and adhere for 30' during which time petri
dishes may be gently agitated once or twice. Gently rinse off super-
natant with PBS until free from loose RBC. (Surface tension will
cause the PBS to peel back, removing the RBC coating, therefore the
petri dish surface must be submerged at all times. Coated dishes may
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be stored at 4°C for up to one week in PBS.) Aseptically remove spleen
of mouse immunized with type 1 cells into 10 ml PBS and tease apart to
free cells (see Methods: preparation of spleen cells). Pour spleen
cells into petri dish #2 and allow to settle and adhere for 30 I with
one or two gentle agitations during this period. Gently rinse off
nonadherent cells and retain in a 100 ml beaker. The nonadherent
cells are allowed to settle or centrifuged so that volume of cell
suspension may be brought down to 5 m1. Resuspend these nonadherent
cells in 5.0 ml P.B.S. and pour onto coated dish #1. Allow to settle
and adhere for 30' with one or two gently agitations. Gently rinse
off and dispose of nonadherent cells. Leave 2-3 ml of PBS in petri
dish. With a pasteur pipette remove the adherent lymphocytes and the
RBC coating and pour into a 15 ml conical centrifuge tube. Add 10 ml
of WBC diluting fluid and mix. 10 minutes is sufficient to rupture
membranes of RBC: Spin cells at 900 g for 5 minutes. Decant supernatant.
The remaining lymphocytes are specific for type 1 RBC antigens, theo-
retically.
VII Preparation of Immune Mouse Serum
Immunization
Human erythrocytes, washed, 20 % cells in PBS
1 ml syringe with 23 gauge needle
10 adult outbred mice
(Immunization against sheep RBC is carried out by the same method,
substituting sheep RBC for human RBC.)
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Collection of Serum
1 Scalpel; LP 3 tube
2 pairs sterile sissors
2 pairs sterile forceps
2 ml syringe with 21 gauge needle (sterile)
Cork board
Pins
5 ml centrifuge tube with cap (sterile)
70% EtOH for swabbing
2 ml vial for storage (sterile)
Centrifuge
Method
Immunization
Prepare 20% human erythrocytes in PBS fresh before each immunization.
1 ° immunization: Inject 0.2 ml of 20% human erythrocytes Lp. into
each adult mouse. 2° immunization: 3-4 weeks later inject 0.2 ml of 20%
human erythrocytes Lp. into the same mice. These mice are ready to be
bled 4-6 days later.
Collection of Serum
4 days following the 2° immunization collect blood from the tail
to determine if the antibody titre is sufficient. Wipe the tail vigorously
with 70% alcohol, massage gently or expose to heat to dilate the vessels
and with a sharp scalpel chop off approximately 1 em. Several drops of
blood may be obtained freely in this manner. Further manipulation of
the tail - that is, attempting to squeeze the veins manually to obtain
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more blood - should be avoided, since this dilutes the blood with
tissue fluids. Allow blood to clot for 30 I at 20°C and centrifuge to
compact the clot. Remove the serum and test at doubling dilutions with
an equal volume of 0.5% human erythrocytes for agglutination. If the
titre of mouse serum is sufficiently high the mouse should be
exsanguinated. To obtain maximal volume of blood, chloroform is
preferred for anesthesia, since it causes dilation, first of the left
atrium and later of the entire heart. Put the mouse into a beaker with
a wire grid bottom under which a chloroform-moistened gauze swab is
present. Close the top with a petri dish. At a deep level of anesthesia
remove the mouse and pin taut by the feet, ventral side up on the cork
board. Wash the chest area with 70 % alcohol. Under sterile conditions
open the chest wall. While the heart still beats, introduce the needle
into the wall of the left ventricle and slowly withdraw the blood.
Practice is essential to obtain the maximal amount of blood (1.5 - 2.0 mil
without clotting or hemolysis. Put the blood into the sterile centrifuge
tube and allow it to clot for 30' at 20°C. (Kill the mouse by cervical
dislocation. l Centrifuge the blood at high speed to compact the clot.
Under sterile conditions remove serum with a sterile pasteur pipette
and transfer to a sterile capped vial for storage at 4°C.
VIII Preparation of H.A.T. and H.T. Mediums
Materials
Hypoxanthine
Aminopterin
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Thymidine
NaOH IN.
Weigh accurately the approximate amounts of each compound in the
table and dissolve in [wt (in mg) x f (in ml) 1 ml of solvent to give 1000X
stock. (f = l/molarity x M.W.) Store in -20°C freezer in dark as
separate solutions.
Convenient
Compound ~ Approx. Wt. ! molarity
Hypoxanthine 136.1 15 mg 0.074 1.0 x 10-
1
Aminopterin 440.43 1 mg 5.54 5 x 10-
4
Thymidine 242.23 30 mg 0.138 3.0 x 10-
2
Hypoxanthine requires '" 100 u l. IN. NaOH for solution
Aminopterin requires '" 50 u l. IN. NaOH for solution
Subtract these volumes from f x wt to get total ml water to be added
to give desired molarity.
Take 0.1 ml of each solution and add 9.6 ml RPMI (oMEM) to make
lOX Stock. (omit aminopterin and use 9.7 ml RPMI (DMEM) for lOX HT
stock) .
For complete HAT (or HT). H: 10-4 M; A: 5 x 10-7 M; T: 3 x 10-
5
M
Fetal calf serum 2 parts
lOX Stock solution 1 part
RPMI (or DMEM) 7 parts
2-Mercaptoethanol 5 x 10-5 M
Antibiotics 1 %
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Toxicity Testing of Mediums
It is necessary to ensure that the various mediums are correctly
constituted and produce the desired effect on tumor cells and on
normal cells. That is DMEM, HAT and HT should not be toxic to normal
cells. DMEM and HT should not be toxic to tumor cells but HAT should
be toxic to tumor cells. New batches of FCS should be tested to ensure
they are not toxic to either cell type.
Equipment and Materials
Inverted phase contrast microscope
Light microscope
Linbro plate - 24 wells
2.0 ml pipettes
10 ml pipettes with 0.1 ml graduations
Mediums to be tested
HAT(lO) medium
HT (10) medium
DMEM (10) medium
Fetal calf serum (FCS) 20% in DMEM
Method
Inject 1 ml thioglycollate broth Lp. into an outbred mouse.
Several days later, remove macrophages from the peritoneum of the
mouse and allow to establish themselves in 12 wells (rows 1 & 2) of
the Linbro tray for several days prior to media testing. The macrophages
should not be confluent for this test. Decant medium from these wells
leaving only enough medium to just cover macrophages (approximately
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0.1 ml.) , Into the 12 remaining wells add 0.1 ml of healthy myeloma
cells adjusted to a density of approximately 1 x 10 6 cellslm1. To the
first well in each of the four rows (column 1) add 2.5 ml of the first
test medium: HAT(10). 2.5 ml of DMEM(lO) is added to wells of column 3.
FCS to be tested is made up as a 20 % solution in DMEM and 2.5 ml are
added to wells of column 4. Columns 5 and 6 may also be used to test
mediums or FCS. Replace the cover on the Linbro plate and incubate
at 37°C for 4 days. Observe the cells using the 40X power on the
inverted phase contrast microscope. An example of the result of media
testing is shown in TABLE II.
Polyethyleneglycol M.W. 1000 (PEG 1000) Preparation, Toxicity Testing
The toxicity of PEG 1000 was tested on MOPC 315.43 cells 1.) with
various concentrations of PEG and 2.) with various exposure times.
8 screw cap centrifuge tubes
24 x 3 ml test tubes
Test tube rack
Centrifuge
2 x 2.0 mL graduated pipettes
Light Microscope with lOX eye piece and lOX objective
MOPC 315.43 cells. 2-3 x 10 6 cells with high viability
RPMI (10) (RPMI with 10 % FCS
RPMI (0) (serum free RPMI
PEG 1000 in RPMI in the following concentrations: 0,30,35,40,45,50,
55,60% v/v.
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~
Heat PEG until it becomes liquid. Meanwhile add to 8 screw cap
centifuge tubes:
tube #
RPMI(O) m1. 2.0 1.4 1.3 1.2 1.1 1.0 0.9 0.8
PEG m1. O. 0 o. 6 O. 7 o. 8 O. 9 1. 0 1. 1 1. 2
[PEG] in % 30 35 40 45 50 55 60
PEG is drawn into a 2 ml pipette. A bunsen flame may be lightly applied
to the pipette to keep PEG liquid while dispensing. As soon as PEG is
added mix by inverting tubes. Autoclave. Centrifuge cell suspension
900g X 5'. Decant supernatant. Make up to 12 ml with RPMI (0) . Resuspend
cells and measure 0.5 ml into each of 24 test tubes numbered Al to A8, 81
to 88 and Cl to C8. Centrifuge tubes at 900 g. Tip each tube to decant
supernatant. Arrange in rack: row 1: tubes Al-A8, row 2: tubes
81-88, row 3: tubes Cl-C8, row 4: PEG solutions 1-8. Place pipette
with bulb in each of the 8 PEG solutions. Set timer and work quickly.
Add 0.5 ml of PEG tube 1 to test tubes Al, 81, C1. Add 0.5 ml of PEG
tube 2 to test tubes A2, 82, C2. Do the same with remaining PEG
solutions. Resuspend cells by tapping test tube rack on bench. At
5' add 1. 5 ml of RMPI (10) to all A tubes and centrifuge 5' at 900 g.
At 10' centrifuge 8 tubes. Decant supernatant in A tubes and add
1. 5 ml RPMI (10). Resuspend cells. A tubes are ready for analysis.
Decant supernatant in 8 tubes and add 1. 5 ml RPMI (10) . Centrifuge
again at 900 g for 5'. Decant supernatant from 8 tubes; add 1.5 ml
RPMI (10) and resuspend cells. 8 tubes are ready for analysis. At 30'
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centrifuge C tubes at 900 g for 5'. Decant supernatant and add 1.5 ml
RPMI (10) • Resuspend cells. Centrifuge 900 g for 5'. Decant supernatant
a nd add 1.5 ml RPMI(lO). Resuspend cells. C tubes are ready for analysis.
Viability of cells is determined by exclusion of trypan blue.
Add 0.1 ml of cell suspension to 0.1 ml of 0.2 % trypan blue. Refer
to methods: counting of myeloma cells.
Fusion of Mouse Myeloma Cells and Mouse Spleen Cells
Protocol #1 (Modification of the procedure of Galfre and Milstein. 4 5)
DMEM(20): DMEM with 20 % Fetal Calf Serum
DMEM(O): Serum free DMEM (DMEM(O))
PEG is made up fresh for each fusion: weigh out approximately 2. a g.
PEG 1500 and autoclaved. When PEG cools to about 55°C, add an equal
volume of DMEM(O).
HT medium: DMEM(20), supplemented with H & T only.
Cloning medium: DMEM (20) supplemented with HAT.
Method: Fusion
Prepare 10 8 spleen cells and put in conical centrifuge tube.
(Method V: Preparation of cell suspensions from mouse spleen cells.)
Add 10 7 myeloma cells. Wash 2X with DMEM(O). Remove supernatant. Add
0.5 ml PEG over 2' (0.1 ml every 20 seconds). Add 0.5 ml of DMEM(O) at
the same rate. Add a further 5.0 ml DMEM(O) dropwise by doubling volume
over every minute for 3 minutes. Fill tube with DMEM(O) Centrifuge for
5' at 900 Xg. Remove supernatant and resuspend pellet in DMEM (20) .
Make up to 100 ml with DMEM (20). Plate out 0.2 ml in each well of
4 x 96 well Linbro microtitre plates.
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Method: Feeding
Remove approximately 1/3 to 1/2 of the culture medium from each
well and replace with Cloning medium. Do this on alternate days from
day 1 to day 19 following the fusion day. On alternate days from day 21
to day 27 replace the removed medium with HT medium. On alternate days
from day 20 onwards replace removed culture medium with DMEM(20).
XII Fusion of Mouse Myeloma Cells and Mouse Spleen Cells
Protocol #2 (Modification of the Procedure I of Andersson and
Melchers. 46)
Myeloma cells NS-l are used in fusion experiments, taken at their
exponential phase of growth. 1 x 10 7 cells used.
Spleen cells from a 1° immunized adult BALB/c are used.
Materials and Equipment
Centrifuge; 37°C water bath
Conical centrifuge tubes - 15 ml
Microtitre plates (Falcon) 96 well, flat bottom
Pipettes
Polyethylene glycol solution 45 % v/v PEG, 15 % v/v DMSO in PBS (PEG/DMSO)
Serum free DMEM (DMEM(O» pH 8
Cloning medium DMEM/HAT with 20 % FCS
Method
Pellet 10 7 myeloma cells and 10 8 spleen cells in a Falcon tube.
Remove medium by suction. Bring temperature of cells up to 37°C and
slowly add 1-2 ml of PEG/DMSO at 37°C (3') to cover the cell pellet.
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Thereafter layer 10 ml of DMEM(O) pH 8 at 37°C slowly (10') above the
PEG/DMSO solution. This mixture is spun at room temperature for 5 I at
200 Xg, the supernatant removed by suction and the cells washed once
with DMEM(O) pH 8. The cells are finally resuspended in full culture
medium and plated in microtitre plates at 0.2 ml per culture. The
culture medium is not changed until the appearance of clones of fused
cells.
XIII Fusion of Mouse Myeloma Cells and Mouse Spleen Cells
Protocol #3 (Modification of the Procedure of Mosmann et a1. 41)
1. Myeloma cells should be healthy and in exponential growth. The
myeloma parent should preferably contain both a resistance and
a sensitivity marker (eg. HGPRT negative and Ouabain resistant)
to allow selection against both myeloma and spleen cell parents.
(Al though the spleen lymphocytes normally die out in tissue
culture, growth of fibroblasts from the spleen cells can
occasionally occur if ouabain is not used.)
2. Spleen cells are prepared as in Methods: Preparation of Cell
Suspensions from Mouse Spleen Cells.
3. Count myeloma cells and spleen cells. Mix in a 50 ml centrifuge
tube in the ratio myeloma: spleen of 1: 10. Minimum number of cells
suggested is 10 7 myeloma to 10 8 spleen cells.
4. Pellet cells at 900 Xg for 10 I • Resuspend in 20 ml RMPI (0)
Pellet cells at 900 Xg for 10'. Remove supernatant.
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5. Tap tube gently to dislodge pellet. Add slowly with mixing 2 ml
of PEG solution.
6. After 2', add dropwise, mixing continuously 20 ml RMPI (0) . The
addi tion should take 3' - 5 I •
7. Pellet cells by centrifugation at 900 Xg for 10 I • Remove supernatant
and dislodge pellet gently by tapping.
8. Add 5 ml RPMI (20) . Do not completely resuspend pellet - leave
as lumps.
9. Incubate with cap loose at 37°C for 1-3 hours. Dilute the fused
cell suspension to a final concentration of 105 myeloma cells/ml
in cloning medium.
10. Mix thoroughly and dispense 200 ~.Q, aliquots to a 96-well flat
bottom Linbro tray; 2.5 ml aliquots in a 24-well Linbro tray or
5 ml aliquots in petri dishes.
11. Clones of fused cells will normally become apparent in the Linbro
wells after 10-14 days. In a "good" experiment one might expect
about one hybrid per well (96-well tray).
12. Selected clones can be grown up by transferring to fresh cloning
medium B (containing no aminopterin). When the cells reach high
density (1-2 x 105 cells/ml) they can be transferred to RPMI (20) and
eventually RPMI (10) if growth continues.
XIV Cytocentrifuge Preparation of Fusion Products
Equipment and Materials
Cytocentrifuge
Glass slides
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Cytocentrifuge blotting papers
Test tubes
pipettes
Microscope
Haemocytometer
Giemsa stain
Fetal calf serum
Buffer
Trypan blue
Protex (Scientific Products Cat. # M7635)
Count the cells to be prepared under the low power of the
microscope, and dilute 1/2 in trypan blue 0.2%. Note viability,
cell density and types of cells present. Adjust an aliquot of cell
suspension to 1-3 x 105 cells/ml and add an equal volume of fetal
calf serum and mix. Put four drops of this cell suspension (approx.
0.1 mL) into several wells of the cytocentrifuge. Centrifuge at
500 RPM for 5'. Air dry slides. Fix the slides in methyl alcohol
for 2'-5'. Stain in Giemsa (fresh) for 7 minutes. Destain in buffer
30 seconds. Check intensity of stain under low power of microscope
and destain for longer if necessary. Dry in air. Fix coverslip
with Protex.
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XV Inhibition of Antiglobulin Serum as a Method of Estimating
Antibody Production in Hybrid Supernatant
Materials and Equipment
Centrifuge
Microscope
Microscope slides
Sheep erythrocytes
Immune mouse serum (antigen: sheep erythrocytes)
Anti mouse immunoglobulin (Gibco cat # 343-1 specificity: globulin
portion of whole serum)
Universal flask
LP3 tubes or Linbro microtitre plates (round bottom wells)
Preparation of Antigen Coated Erythrocytes (EA)
Sheep erythrocytes are coated as follows: wash sheep cells
3X. Mix 5.0 ml of a 1.0% suspension of sheep cells with 5.0 ml of
a subagglutinating dilution of immune mouse serum (dilution used in
this case 1/256). Allow adsorbtion of the mouse proteins to occur
in overnight incubation at 4°C. Wash cells 3X and resuspended in
PBS at pH 7.2 at 1 x 10 7 cells/m1. Check the cell suspension
with the microscope to ensure no agglutination is visible. These
sheep cells are now antigen coated, refered to as sensitized cells
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Standardization of Antiglobulin Reagent
Anti mouse globulin was obtained commercially (Gibco #343-1).
Prepare doubling dilutions of antiglobulin in 2 sets of 12 tubes
(1 to 1/4096) with 20 )11 final volume in each tube. Put PBS only in
tube 13. Add 20 III of sensitized sheep cells (EA) to each tube and
mix. Allow to stand for 60' at room temperature. Observe the
pattern of agglutination to determine the weakest dilution that
produces strong agglutination. Refering to Table M-l strong
agglutination was seen in tube #6, a 1 in 32 dilution but agglutination
was not strong in the next tube. It is desirable to use antiglobulin
reagent of adequate strength to agglutinate 1 or 2 tubes beyond the
test conditions, yet antiglobulin reagent of too strong a dilution
may not be inhibited by small amounts of mouse globulin which may be
found" in hybrid supernatant. Therefore the antiglobulin reagent was
diluted for use at the dilution two tubes before the end point. That
is the dilution of tube #4, a 1 in 8 dilution.
Controls
The rationale of this test is the ability of mouse globulin to
inhibit the agglutination of EA by the antiglobulin reagent. This is
tested as follows. Make doubling dilutions in duplicate (20 III each
tube) of immune mouse serum - ten tubes. Put RPMI (20) in tube 11 and
12. To each of the tubes 1 to 11 add 20 III of EA. Leave tubes
undisturbed at room temperature for 60'. Observe the pattern of
agglutination.
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Table M-2 shows the outcome of such a test. From these results
controls were obtained to be used in running tests of antiglobulin
inhibition by hybrid supernatant.
immune mouse serum (antigen human erythrocytes) inhibited
agglutination completely in tubes 1 to 7 (dilution 1 to 1/64).
This control ensures that agglutination can be inhibited by
small amounts of antibody. The dilution of tube 6, that is 1
in 32 dilution is used in all test runs to ensure that the
system can be inhibited.
RPMI (20) does not inhibit agglutination. This control
ensures that culture medium in which hybrid cells are
grown does not inhibit agglutination. A single tube of
RPMI (20) in which EA and antiglobulin reagent are added
is used in test runs as a control.
RPMI (20) in the absence of an antiglobulin reagent shows no
agglutination. This control ensures that EA are not being
agglutinated due to something other than antiglobulin. A single
tube RPMI (20) in which EA but no antiglobulin reagent is added
is used in test runs on hybrid supernatant as a control.
Ficoll Hypaque Separation of Viable Myeloma Cells
Ficoll Hypaque: density 1. 082 Screw cap centrifuge tube
Myeloma cells: 1 x 10 7 cells (minimum) in serum free medium
Layer approximately 2 ml of cell suspension on an equal volume
of Ficoll Hypaque in the centrifuge tube. Following Centrifuge for
30' at 400-425 g. Using a pipette, remove cells from the interface.
Viability ranges from 78-96%, and 85 % of cells are recovered.
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Table M-l
Agglutination of Sensitized Sheep Cells by Commercial Anti-Mouse
Globulin
Anti Mouse Globulin:dilution
1/2
1/4
1/8
1/16
1/32
1/64
1/128
1/256
1/512
1/1024
1/2048
1/2096
-ve control PBS
Sensitized Sheep Cells
present
Agglutination
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Table M-2
Inhibition of Agglutination of Sensitized Sheep Cells by Inunune Mouse Serum
Inunune Mouse Sensitized Antiglobulin
Tube# Serum Dilution Sheep Cells Reagent 1/8 diln Agglutination
(EA)
present present
Not present
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TECHNICAL DEVELOPMENT
The hybridoma technique had not been set up in the province before
this time so it was my task to develop it from its beginning. It was
decided at the outset of the program not to plunge into the core
experiment immediately but to save time later each component of the
experiment was first established and practiced.
Elements of the experiment include:
(1) Optimizing conditions for growth of tumor cells
(2) Testing media and reagents before use
(3) Imrnunization of donor mouse
(4) Choice of inbred mouse strain
(5) Assays for antibody formation by hybridomas.
Optimizing Conditions for Growth of Tumor Cells
Cell line NS-l
The myeloma line used in the early research work was P3-NSI-I-Ag4-1.
Its shortened name is NS-l~9 This tumor cell line was obtained through
Dr. Elizabeth Simpson of the Clinical Research Center in Harrow, U.K.
and is from the original line of Dr. C. Milstein of MRC Institute for
Molecular Research, Cambridge, England. This cell line was grown under
the conditions given in the methods section.
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Cell line MOPC 315.43.
In later experiments the mouse plasmacytoma MOPC 315.43 was used.
This cell line40,41 was obtained from Dr. T. Mosmann through Dr.
Lee of the University of Alberta in Edmonton, Alberta. The conditions
used for growth of this cell line were identical to that of NS-l except
that RPMl (Gibco Cat # 380-2400) was substituted for DMEM (Gibco
Cat # 320-1885).
Effect of Cell Concentration on Viability
The viability of myeloma cells was investigated at various cell
concentrations. A suspension of NSI myeloma cells shown by trypan
blue exclusion to have a concentration of 3.7 x 105 cells/ml and
viability of 94% was subcultured at various concentrations. These
subcultures were examined at 24 hour intervals for viable cell con-
centration.
From the results - NS-l cells concentration dependence GRAPH I -
a number of conclusions were drawn:
1. Growth rate of the myeloma cells is not entirely predictable
particularly when cell concentration is less than 2.5 x 10 4
cells per ml or greater than 4 x 105 cells/ml.
2. Exponential growth of myeloma cells occurs when the cell con-
centration is within the range of 2.5 x 10 4 cells/ml to 4 x 105
cells per ml.
3. The viability of the myeloma cells is highest when the cells are
in their exponential growth phase.
4. Doubling time for the NS-l cell line is 13 hours under the conditions
attained during the exponential growth phase.
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GRAPH I (a)
NS-1 CELL CONCENTRATION DEPENDENCE IN DUPLICATE CULTURES
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GRAPH I (b)
NS-1 CELL CONCENTRATION DEPENDENCE IN DUPLICATE CULTURES
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GRAPH I (c)
NS-1 CELL CONCENTRATION DEPENDENCE IN DUPLICATE CULTURES
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GRAPH I ( d )
NS-l CEL L CONCENTRATION DEPENDENCE I N DUPLICATE CULTURES
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GRAPH I (e)
NS-l CELL CONCENTRATION DEPENDENCE IN DUPLICATE CULTURES
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GRAPH I(f)
NS-l CELL CONCENTRATION DEPENDENCE IN DUPLICATE CULTURES
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GRAPH I(g)
NS-l CELL CONCENTRATION DEPENDENCE IN DUPLICATE CULTURES
PLATING DENSITY 8 x 105 CELLS/ML.1"10~r------------------:...--------,
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GRAPH I (h)
NS-l CELL CONCENTRATION DEPENDENCE IN DUPLICATE CULTURES
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5. When cells reach a maximum concentration of approximately 8 x 105
to 4 x 10 6 they rapidly begin to die off. The drop in concentration
of viable myeloma cells may be exponential within 24 hours.
Testing Media and Reagents Before Use
Fetal Calf Serum (FCS)
Toxicity of some batches of FCS to the myeloma cells indicate the
need to screen FCS before use. This was done using 10% FCS plus culture
medium for growing myeloma cells in a test in which properly functioning
FCS and medium was used as a control. The growth rates in duplicate
cultures of both batches of FCS with medium indicated if the FCS was
toxic.
Batches of ' HAT (Hypoxanthine (H) Aminopterin (A) and Thymidine (T»
and HT (Hypoxanthine (H) and Thymidine (T» supplemented medium (Methods:
Preparation of H.A.T. and H.T. Mediums) were tested on two types of cultures
1) Myeloma cells and 2) mouse peritoneal macrophages. Duplicate
cultures were examined after 3 days at which time it was expected
that the myeloma cells would have failed to grow in HAT but not HT
and the macrophages should be healthy in both mediums. Data from one
test appears in TABLE I.
These results are typical. It can be seen in TABLE I that NS-l
myeloma cells grown in HAT supplemented medium start dying off by day 3.
Whereas NS-l myeloma cells grown in HT supplemented medium proliferate,
doubling nearly 3X in this period. This is similar to the growth
observed in the control cultures.
TABLE I
Effect of Various Media on Cell Proliferation
MYELOMA CELLS
in DMEM (10)
(Control)
in HAT in HT
Day 1 a) 4 x 104 b) 6 x 10 4 a) 4 x 10 4 b) 6 x 10 4 a) 4 x 10 4 b) 6 x 10 4
Plating density cells/ml cells/ml cells/ml cells/ml cells/ml cells/ml
Day 3 a) 2 x 10 5 b) 3.2 x 10 5 a) 2.1 x 10 4 b) 1.1 x 10 4 a) 2.7 x 10 5 b) 3.1 x 10 5
I Ce l l count cells/ml cells/ml cells/ml cells/ml cells/ml cells/ml0
I!'l
I
MOUSE PERITONEAL MACROPHAGES
in DMEM (10) in HAT in HT
(Control)
Day 1 a) healthy b) heall:hy a) healthy b) healthy a) healthy b) healthy
subcon- subcon- subcon- subcon- subcon- subcon-
fluent fluent fluent fluent fluent fluent
Da y 3 a) h ealthy b) healthy a) healthy b) healthy a) healthy b) healthy
subcon- subcon- sub c o n- subcon- subcon- subcon-
fluent fluent fluent fluent fluent f l ue n t
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Mouse peritoneal macrophages are not effected by HAT supplemented
or HT supplemented media. The health and density of these cells remain
unchanged following 2 days of growth in supplemented media, being
indistinguishable from control cultures grown in unsupplemented medium.
The HAT medium tested inhibits proliferation of myeloma cells but
has no detrimental effect on macrophages. HT medium tested shows no
detrimental effect on myeloma cells or macrophages.
Polyethylene Glycol (PEG)
Higher concentrations of PEG and increased exposure time favour
fusion of cells but increase toxicity to the cells. 19,30 Maximum PEG
concentration and PEG exposure time were to be chosen that result in
cell viability of not less than 80 %. PEG was prepared in 7 dilutions
and tested for toxicity against myeloma cells in 5, 10 and 30 minute
exposures.
Appears in methods section.
As seen in GRAPH II increasing the time that myeloma cells are
exposed to PEG or increasing the concentration of PEG decreases viability
of the exposed cells. In 5 I exposures of PEG up to a concentration of
45 % over 80% of the cells remain viable compared to the viability of
cells exposed to 0 % PEG. Concentrations of greater than 45% PEG cause a
substantial decrease in viability of the myeloma cells.
In a 10 I or 30' exposure the viability of the myeloma cells exposed
to 30 % to 45% PEG drops considerably compared to cells exposed to 0 % PEG.
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VIABILITY OF MYELOMA CELLS EXPOSED TO VARIOUS CONCENTRATIONS OF
PEG FOR 5, 10 AND 30 MINUTES
• __•••.•. 5 MINUTES
x__ 10 MINUTES
0------...30 MINUTES
6'05'0
O. ·.L.-__-:--__-;--__--:--__--:-__--:-__--:"__~
o
CONCENTRATION OF PEG (% OF MIXTURE AND MEDIUM)
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5' exposure of cells to 45 % PEG and 10' or 30' exposure to 35 %
PEG results in > 80 % myeloma cell viability under the test conditions.
The 5' exposure to 45 % PEG was chosen to be used in all of the fusions
carried out in this paper.
Immunization of Donor Mouse
One factor which influences the yield .o f hybridomas of desired
specificity is the prior immunization of the mouse whose spleen is to
be used in the fusion. In order to discover the time of peak activity
in the spleen after immunization a plaque assay was used. Several
mouse strains were compared to find which ones made a satisfactory
response to human RBC; the latter point is described in Section IV.
Method
The plaque method, based on that of Jerne is used4 7, in which spleen
cells are counted and applied with complement over a thin layer of RBC in
gel. Appearance of hemolytic plaques indicates spleen cells which form
antibody to RBC.
TABLE II shows the plaque response by mouse spleen cells following
immunization with sheep RBC. The number of plaques on days 3 and 4
post-immunization is not substantially more than the background level
(the number of plaques produced by the spleen of a non immunized mouse) ,
although the serum titre increases steadily. On day 5 peak activity is
observed in the spleen in terms of highest number of plaques. Activity
in the spleen in terms of number of plaques produced drops sharply
after day 5 although the serum titre continues to rise. Peak activity
occurs in the spleens of mice immunized with sheep RBC on day 5 post-
immunization.
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Analysis of Haemolytic Titre and Jerne Plaque Response to~ RBC in
3 Strains of Mice
SHEEP
C57 NOT IMMUNIZED RED BLOOD
CELLS
BREED
C3H
BALB/c "
C57
C3H
BALB/c
C57
C3H
BALB/c
C57
C3H
SHEEP
RED BLOOD
CELLS
INDICATOR POST-IMMUNIZATION HAEMOLYTICTIME (DAYS) TITRE (SERUM)
1/4
1/4
1/8
1/2
1/2
1/4
1/2
1/2
1/2
1/2
1/4
1/2
1/2
1/2
1/4
1/8
1/2
1/8
1/32
1/32
1/32
1/16
1/32
1/16
1/32
1/64
1/16
1/512
1/1024
1/512
1/256
1/512
1/512
continued.
PLAQUES/l06
48
40
29
49
55
43
TABLE II (continued)
BREED ANTIGE N
BALB/ c
C57
C3H
BALB/ c
- 5.5-
I NDICATOR POST-IMMUNIZATION HAEMOLYTIC PLAQUES/l06TIME (DAYS) TITRE (SERUM)
1/512 41
1/1024 53
1/512 61
1/2048 41
1/2048 10
1/2048 11
1/32 29
14
1/2048 23
1/1024 10
1/2048 17
1/102 4 9
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Several attempts were made to produce similar results using
human erythrocytes as an antigen but there were virtually no plaques
detected. TABLE VII shows the plaque response by mouse spleen cells
following immunization with human RBC. Although the serum titre is
highest at day 6, (much the same as seen in mice immunized with
sheep RBC - TABLE II) activity detected in the spleen remains
unchanged from the background level.
It was decided to be guided in the present work by immunization
schedules published in the literature which had been satisfactory for
other antigens48,49. Four days after primary immunization the spleen
was removed for the fusion.
Choice of Inbred Mouse Strain
Comparison of haemolytic titres were made in C3H, BALB/c and
C57BL/6 strains of mice.
Triplicate tests were carried out in each of the 3 strains of
inbred mice. Each received one intraperitoneal injection of 0.4 ml
of a 20% suspension of washed human or sheep RBC. Four days later
blood was removed from the mouse by cardiac puncture, allowed to clot
and the serum prepared by double dilutions with PBS. An equal volume
of washed 3% suspension of the same type erythrocytes was added.
hour later the pattern of hemolysis was observed.
Table II and III shows the hemolytic response of C3H, BALB/c and
C57 strains of primary immunized mice against human and sheep RBC.
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Analysis of Haemolytic Titre in Serum and Jerne Plaque Response of Spleen Cells
to Human RBC in 3 Strains of Mice
BREED ANTIGEN TIME (DAYS) HAEMOLYTIC 6*TITRE (SERUM) * PLAQUES/10
NOT HUMAN 1/2
C57 IMMUNIZED RED BLOOD 1/2
CELLS 1/2
1/2
C3H 1/4
1/8
1/2
BALB/c 1/2
1/4
HUMAN 1/2
C57 RED BLOOD
CELLS 1/2
1/4
C3H 1/8
1/16
1/2
BALB/c 1/4
1/2
1/32
C57 1/32
1/32
1/16
C3H 1/32
1/32
1/32
BALB/c 1/64
1/64
1/512
C57 1/512
1/2
1/512
C3H 1/1024
1/1024
* Each measurement represents the value for one mouse.
continued •.•
TABLE III (c o n t i n ued )
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BREED
BALB/ c
C57
C3H
BAL B/ c
ANTIGEN TIME (DAYS) HAEMOLYTICTITRE (SERUM) *
1/512
1/512
1/256
1/1024
1/1024
1/2048
1/1024
1/1024
1/2048
1/2048
1/16
PLAQUES /l0 6 *
* Each measurement represents the value for one mouse .
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It can be seen that the humoral antibody response to both antigens, as
examined in three strains of mice increases steadily from day 3 to
day 6. The three mouse strains studied were not significantly different
in terms of hemolytic titre observed on days 3,4,5 or 6 or in the case
of non-immunized mice.
Conclusion
Choice of one strain of mouse could not be made based on these
data. All strains are equal in terms of hemolytic response.
Assays for Antibody Formation by Hybridomas
Two approaches were considered desirable (i) to assay for
immunoglobulin (Ig) production by the hybridoma (ii) to assay for
production of specific antibody to human red cells. It was expected
that many more wells would contain mouse Ig than would contain specific
anti RBC antibody.
Assay for mouse Ig
It was expected that amounts of Ig would be small, in the super-
natants of initial cultures. Therefore an inhibition of the anti-
globulin test was set up and its sensitivity tested. Se e Table IV.
Method
The method finally arrived at made use of a rabbit anti-mouse
globulin antibody and sheep RBC sensitized with subagglutinating doses
of a mouse anti-sheep RBC antibody that was obtained from nonabsorbed
mouse sera from mice injected on 3 occasions with 0.4 ml of washed
sheep erythrocytes.
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Results
A panel of results given in TABLE IV show that this test is
capable of detecting the inununoglobulin in normal mouse serum
undiluted (b) through to dilutions of up to and including 1/64 (h).
The control (a) in which saline is added to the rabbit anti-mouse
globulin antibody shows no inhibition of agglutination of the sheep
cells. The same result is seen in tests in which very small amounts
of mouse serum are present; ie. dilutions of greater than 1/64 (i & j).
Conclusion
The wide range of inununoglobulin concentrations over which this
test is sensitive makes it suitable for screening supernatants in
which colonies are found.
Assay for specific anti-human RBC antibody
After preliminary trials it seemed that agglutination would be
superior to haemolysis as an assay. The method used is conceptually
simple and involved mixing 4 volumes of supernatant with 1 volume of
washed 3% RBC suspension in a round bottom microtitre tray and incubating
at 37° for one hour. These trays were then centrifuged at 3000 r.p.m.
for 5' and then checked macroscopically for agglutination.
Results
Table V shows the results of this test using Lmmune mouse serum (antigen
human RBC) as a positive control and using supernatant from a well in which
a hybridoma colony was present but no inununoglobulin was detected as
the negative control. Strong agglutination was apparent when inunune
mouse serum was used to agglutinate the human erythrocytes. The
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TABLE I V
Inhibition of Antiglobulin Test
Test # Rabbi t Pooled normal
antimouse Ig
antibody
Sensitized Agglutination
sheep cells of sheep cells
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TABLE V
Test of direct agglutination assay for
anti-human antibody
Test solution
+ve control
(immune mouse serum:
antigen human RBC)
dil 'no 1
dil'n. 1/2
1/4
1/8
1/16
1/32
1/64
1/128
-ve control
(tissue culture medium
from wells containing
no clones)
Direct agglutination
of human RBC
(+++)
(+++)
(+++)
(+++)
(+++)
(+++)
(++)
(+-)
(-)
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positive control of this assay utilized undiluted immune mouse serum.
Dilutions of the serum from 1/2 to 1/64 gave a positive result, in
which strong agglutination was seen. A dilution of 1/128 gave a
negative result, in which agglutination was borderline (+-).
Agglutination in the negative control was a definite negative (-).
Direct agglutination of human erythrocytes is a suitable assay
to detect the presence of anti-human RBC antibody in supernatants
of hybridoma colonies. Supernatants of hybridoma colonies do not
appear to contain any other material which interferes with this test.
FUSION RESULTS
Thirty five attempts at fusion were carried out as shown in
TABLE VI. As c~n be seen, apart from three minor productions of
presumed hybridoma colonies the technique did not yield significant
numbers of colonies until after 26 fusions had been completed.
During the earlier experiments various modifications of the
method were tried:
Fusions 2-6 The myeloma cells were enriched for viable cells by
a one step discontinuous density separation on Ficoll.
This produced 92 - 95 % viable myeloma cells for the
fusion. Fusion 3b produced 5 presumed hybridoma
colonies. (Refer to Methods XVI)
Fusions 3 & A feeder layer of mouse peritoneal macrophages 50 in
5-12 subconfluent amounts was used in an attempt to improve
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culture conditions. In fusion 3a and b colonies resulted in
the control wells (those without macrophages) but none resulted
in those wells containing macrophages and so the use of the
feeder layer was not considered advantageous.
Fusions 6-12 Cell selection procedures were performed on spleen cells
before the fusion. This modification was abandoned due
to indications in the literature that input of low
numbers of cells prevented fusion with the protocol
being used. (Refer to Methods VI)
In view of the fact that 17 fusion experiments had been performed in
which only one produced hybridoma colonies, the problem of cell
viability was given closer attention. Exposure to PEG as called for
in the fusion protocol causes a drop in viability to approximately
80 % of that of input cells (GRAPH II). Monitoring the viability of
spleen and myeloma cells before, immediately after and 24 hours after
the fusion was considered desirable. In most cases viability over the
next 24 hours remained relatively unchanged, and in some cases dropped
slightly.
Fusions 18-35 Monitoring of viability of cells was carried out in
all fusions. In cases in which viability of input cells
was below an acceptable level, that fusion experiment
was abandoned. Referring also to TABLE VII it may be
seen that viability of myeloma and spleen cells used
in fusions 18 - 35 was not lower than 86 % and 91 %
respectively. As the TABLE shows, in fusion experiments
in which the viability remains high throughout and
Fusion Experiments I - 35
Fusion Protocol* Variations*
# of
myeloma
cells
# of # of
spleen colonies
cells
# of Ig +ve
by aggn.
inhibition
# of Ab +ve
by direct
aggn.
additional
comments
none, NS-I cells IxlO 7 IxlO8
NS-I,
IxlO 7 IxlO 8myeloma cells Ficolled
giving 93 % viability
I NS-I,
\D 1. 5xlO7 IxlO 8I 3 I myeloma cells Ficolled
giving 92 % viability
NS-I,
plated on masoophage
feeder layer
NS-I,
plated without feeder
layer
NS-I,
IxlO 7 IxlO 8myeloma cells Ficolled
giving 95 % viability
NS-I,
IxlO7 IxlO 7Ficolled: 96 % viability
spleen cells +&- select-
ed; feeder layer used
TABLE VI (cont I d)
# of # of # of # of Ig +ve # of Ab +ve additional
Fusion Protocol* Variations * myeloma spleen colonies by aggn. by direct comments
cells cells inhibition aggn.
NS-l,
lxl0 7 7xl0 6Ficolled: 94% viability
spleen cells +&- select-
ed; feeder layer used
none, NS-l lxl0 7 lxl08
NS-l cells,
lxl07 lxl08spleen cells +&- select-
ed; feeder layer used
lxl07 lxl08
I
'" lxl07 lxl08
'"
10 1I
11 1 lxl07 lxl08
12 1 lxl0 7 lxl08
13 2 none, NS-l lxl0 7 lxl08
14 2 none, NS-l lxl0 7 lxl08
15 2 immunogen: sheep lxl0 7 lxl08
erythrocytes; NS-l
16 2 none, NS-l lxl07 lxl08
17 2 none, NS-l lxl07 lxl0 8
TABLE VI (cont' d)
# of # of # of # of Ig +ve # of Ab +ve additional
Fusion Protocol* Variations* myeloma spleen colonies by aggn. by direct comments
# cells cells inhibition aggn.
18 3 MOPC 315.43 cells; lxl07 lxl08 8 cells lost
viability monitored; through incub-
no ouabain ator failure
19 3 lxl07 lxl08 2 cells lost
through incub-
ator failure
I 20 3 MOPC 315.43 cells; lxl0
7 lxl08
\D viability monitored;
1 ouabain used
21 3 lxlO 7 lxl08
22 3 lxlO 7 lxl08
23 3 lxl0 7 lxl08
24 3 lxlO 7 lxl08
25 3 lxl07 lxl08
26 3 lxl0 7 lxl08
27 a 3 MOPC 315.43 cells; 0 possibility of
viability monitored; ouabain inter-
ouabain lxl0 7 lxl08 ference
MOPC 315.43 cells; 18 9 0 non specific
viability monitored; Ab only
no ouabain
TABLE VI (cont I d)
# of # of # of # of Ig +ve # of Ab +ve additional
Fusion Protocol* Variations * myeloma spleen colonies by aggn. by direct comments
# cells cells inhibition aggn.
28 3 MOPC 315.43 cells; lxl07 lxl08
viability monitored;
ouabain
29 3 lxl07 lxl08
30 3 MOPC 315.43 cells; lxl07 lxl08 16 8 1 antihuman Ab
viability monitored;
no ouabain
31 3 lxl0 7 lxl08 43 24 1 antihuman Ab
co
lxl07 lxl08
'"
32 3 MOPC 315.43 cells;I
viability monitored;
no ouabain, immunogen:
sheep erythrocytes;
33 3 MOPC 315.43 cells; lxl0 7 lxl08 28 17 0 non specific
viability monitored; Ab only
no ouabain, immunogen:
human erythrocytes
34 3 MOPC 315.43 cells; lxl07 lxl08
viability monitored,
no ouabain, immunogen:
sheep erythrocytes
35 3 MOPC 315.43 cells; lxl0 7 lxl08 37 24 2 antihuman Ab
viability monitored;
no ouabain, immunogen:
human erythrocytes
* ~~~ ~~~~i~;~ns used in the fusion experiments are described in detail in the methods section,
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following the fusion step the incidence of hybridoma
colony formation is considerably higher than in those
fusions in which the viability of the cells following
fusion is low. Referring to TABLE VII, in 9 cell cultures
in which mean viability of cells immediately after fusion
is less than 70% (cultures 20- 24, 26, 29, 32 & 34) no
hybridoma colonies developed, whereas in the 10 cultures
in which viability of cells immediately after fusion is
70% or higher (cultures 18, 19, 25, 27a, 27b, 28, 30, 31,
33 & 35) seven of these later developed hybridoma
colonies.
Some further variations were used in fusions 18-35:
Fusions 20-27a Ouabain was added to the cultures following the fusion
step. The use of ouabain to inhibit growth of fibroblasts
from spleen cells resulted in a drop in viability of cells
in the 24 hours following the fusion. As the growth of
non-hybridised spleen cells had caused no problem and in
view of the drop in viability, the use of ouabain was
discontinued.
Fusions 18, Ouabain was not added to these cultures. The viability
19 & 27b-35 in these cultures remained high throughout fusion
moni toring , and a large number of these fusion experiments
produced hybridoma colonies. The high correlation between
viability and hybridoma colony formation is considered
significant.
TABLE VII
Viability Monitoring of Cells of Fu siol)s 18 - 35
viability of* viability of* mean viability mean viability mean viability hybridomaf
Fusion myeloma cells spleen cells of cells b efore of c ells immed- of c ells 24 hours c o l o n i e s
(lx107) (lx108) fusion iate1 y after a fter fus ion p r e sen tfusion
18 89 % 94 % 94% 71 % 68%
19 90 % 94 % 94 % 79 % 72%
20 86 % 92 % 91 % 23% 23%
21 89 % 91% 91% 21 % 24%
22 8 6% 95 % 94 % 48 % 24%
23 87 % 95 % 94 % 49 % 23%
24 8 9 % 9 5% 94 % 51% 21%
25 86% 9 6 % 95% 71 % 54%
26 9 6% 91% 91% 69% 52%
I 27a 90 % 91 % 91% 73 % 58%0
b 90 % 91% 91% 73 % 69%
28 86 % 93 % 92% 70 % 73%
29 90 % 91% 91% 69% 50%
30 89 % 91% 91% 71 % 84%
31 86 % 96 % 9 5 % 70 % 79%
32 89 % 95 % 94 % 68% 72%
33 90 % 96 % 95 % 73 % 79%
34 86 % 96 % 95 % 51 % 43%
35 89 % 96 % 95 % 74 % 81%
f refer to Table X
* f us i o n experiments were dis continued if the v i ability of either myeloma cells or spleen cells was
below 85% or 90% respectively
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Hybridoma incidence and quality
Several days after fusion small white pinhead size clumps became
macroscopically visible in some of the wells. Examination of these with
the inverted phase microscope showed colonies of spherical cells,
confluent and several layers deep. Over the next few days the colonies
became larger and the morphology of the cells remained the same. Ouabain
can be used in fusions with Mope 315.43 in order to kill unfused spleen
cells some of which can survive in tissue culture. Although ouabain
was not used the rapidly developing colonies were believed to be
hybridoma colonies. The rapid proliferation of cells is characteristic
of hybridoma cells, where as those spleen cells which survive and
proliferate are commonly fibroblasts which are slow growing fusifoid
or irregularly shaped cells.
In five out of nine fusions in the final (after fusion 26) phase
of this work hybridoma cell colonies were noted in some of the wells.
From their distribution in the wells it was concluded that there were
152 separate colonies present in 112 wells.
Evidence of immunoglobulin production:
Referring again to TABLE VI - it is observed that supernatants of
152 separate colonies were tested for their ability to inhibit
agglutination of sheep cells sensitized with a sub-agglutinating
amount of mouse serum. Of the supernatants of the 152 colonies, 82
are seen to inhibit agglutination. These are therefore considered
to contain immunoglobulin produced by the cells of the colony.
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Evidence of antibody production against the human RBC used for
immunization:
Referring to TABLE VIII - assay for anti-human RBC antibody -
it is seen that of 82 immunoglobulin containing supernatants only
four agglutinated the human RBC that had been used for immunization.
All other clone supernatants which were found to contain immunoglobulin
by the inhibition of agglutination assay were tested for direct
agglutination of the specific human RBC and found to be negative.
The supernatants of the four positive assays are concluded to contain
antibody directed at the specific human RBC surface antigen (s). The
supernatants from these four clones were diluted to determine the
strength of antibody present. From the table the titre of these
supernatants range from 1/64 to 1/1024.
Three days later these supernatants were again tested for ability
to agglutinate the specific human RBC. The volume of supernatant had
been doubled by medium required to nourish the growing hybridoma colony,
therefore with a dilution factor of 2 one can see if antibody formation
had continued during the next 3 days. Consulting the table, it is
seen that amount of antibody in terms of the titre has reached the same
level in 3 cases and has increased in one case.
Evidence for species specific antibody:
Red blood cells of several species of mammal plus a bird were
tested against the supernatants of clones F30-Dl, F31-A3, F35-A4 and
F35-E4 for direct agglutination. Examining TABLE IX - Agglutination
of cells of these various species - it is seen that supernatants from
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TABLE VIII
Assay fo r Specific Anti-Human RBC Ant i body
su p e r na t a n t
of clone #
F2 7b - Al
-A9a
-A9b
-B3
-C4b
-L7
-L9
-M9
-07
F3 0- B4
-B6b
-01
-Glc
-N4a
-N4b
-N5
-N6
F 31 - A3
-AS
-01
-03
-07
-M4a
-M4b
-M5
-M6
-N6
-07
-09
direct agglutination
of specific human RBC
t itre (2 1 da ys
po s t f usion)
1/256
1/1024
titre ( 24 days
post f u sio n)
1/256
1/10 24
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TABLE VI II (cont' d )
s up e r na t ant
of clone #
F 3 l - 0 11
- 0 12
-Q3
- Q4
-Q6
- R3
- R4
- 5 3
- 5 4
-56
- T2
F 3 3- Al
- A2
- A3a
- A3b
-A3c
- Nl
-012a
-P3
-P12
-Q3
- Q7a
-53
-56
-SSb
- T1 0
- USa
-USb
direct ag glu tinatio n
. o f specific human RBC
titre (21 days
p o s t fusion)
ti t r e (24 days
p o s t fusion)
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TABLE VIII (cont 'd)
s uper na t a n t
of clone #
F3 5- Al
-A2a
-A4
-A6a
-A6b
-A6c
-ci
-E4
-E6
-E7b
-Ec
-Ed
-Ell
-F7
-G8
-Hl
-H2
-H7
-H8
-Hll
-Ml
-S2b
-T7a
-T7b
direct agglutination
of specif ic human RBC
ti t r e (2 1 days
post fusion)
1/64
1/64
t i t r e ( 24 days
p os t f u s i o n )
1/128
1/64
+ve control
(immune mouse
serum)
-ve control
(tissue culture
medium from wells
containing no
clones)
1/64 1/64
-76-
TABLE I X
Agglutination of RBC of Various Species of An ima l s
agglutination of cells using supernatant
of clone #
species of
RB cells
goat
pig
dog
rabbit
guinea pig
s heep
chicken
+ve control
(human)
- ve control
(tissue c u lture
me d ium from wells
containing no
clones)
F30-DI F31-A3 F35-A4 F35-E4
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these colonies were unable to agglutinate the cells of any of the
species tested. The antibodies found in the four supernatants are
therefore considered to be specific for antigen (s) found on the
human RBC.
Evidence that the antibody is directed at a conunon surface antigen
of the human RBC:
A panel of cells from 87 human volunteers was prepared to test the
ability of the antibodies of the four clones for direct agglutination.
The panel of volunteers was chosen at random and contained the conunon
blood groupings listed in TABLE X. Refering to the table, it is seen
that in all cases agglutination of the cells was caused by antibodies
in each of the four supernatants. The antibodies present in the clone
supernatants are therefore considered to be directed at an antigen which
is likely to be conunon to most human red blood cells.
Evidence of the class of antibody:
The four supernatants which were considered to contain anti-human
antibody were tested to determine the class of antibody. An equal volume
of 0.1 molar 2-Mercaptoethanol was added to each supernatant and mixed.
Following thirty minutes incubation at 37°C the solutions were tested
for ability to agglutinate human RBC.
Results
Referring to TABLE XI - agglutination of HRBC (human red blood
cells) following 2-Mercaptoethanol treatment of clone supernatant -
supernatants from clones F30-Dl, F31-A3, F35-A4 and F35-E4 no
longer agglutinated human RBC, but the control, serum from hyper-
inununized mice (therefore containing IgG) agglutinated human RBC.
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TABLE X
Agglutination of RBC of a Panel of 87 Human Volunteers
agglutination of cells using supernatant
of clone #
agglutination of a panel*
of RBC of human volunteers
(87 individual tests)
F30-Dl F3l-A3 F35-A4 S35-E4
*Antigens present on the surface of cells t ested were: D,C,E,c,e,M,N,S,s,A,B,
P,Lua ,LUb, K,k,Lea ,Leb ,Fya ,Fyb,Jka ,Jkb ,Kpa ,Kpb
Antigens present on the surface o f t he inununising cells we r e: D,C ,c ,e ,N ,s ,
K,k ,Leb , Fy a , Fyb , J k b , Kp b.
TABLE XI
Agglutination of HRBC
Following 2ME Treatment of Clone Supernatant
I
(j)
I
Supernatant of
clone #
Di rect agglutination
of human RBC
Direct agglutination
of human RBC following
2ME treatment
F30-DI F31-A3 F35-A4 F35-E4 +ve control
(immune
mouse serum)
-ve control
(tissue cul, t-
ure medium)
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Conclusion
The inability of the supernatants to agglutinate human RBC
following treatment with 2-Mercaptoethanol indicates that antibody of
the Ig M class is present in the supernatant of all four clones.
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DISCUSSION
The approach used in the lymphocyte hybridoma investigation was
to break down the experiment into small components and evaluate each
one systematically. This approach is considered essential. Less than
optimal conditions in one component of the experiment can result in
complete lack of hybridoma formation. Thus when the experiment is
carried out as a whole it is very difficult to identify the source
of the problem and to eliminate it. The technical development section
of the results deals with these components of the experiment.
The optimal conditions for growing the myeloma cells were arrived
at through a process of controlled adjustment of growing conditions.
The optimal temperature and choice of cell culture medium as indicated
in the literature were accepted. In addition, an examination of the
effect of cell concentration on growth of viable cells indicated the
best feeding protocol for the cells. The exponential growth phase of
the myeloma cell could thus be coincided with the intended day of
fusion, ensuring a higher viability of myeloma cells. Problems of
the probability of a mycoplasma infection in one strain of myeloma
cell (NS-l) directed that the work should continue using the MOPC 315.43
line of myeloma cell. Consequently, some of the studies and conclusions
drawn on the NS-l cell work were used as a guide for MOPC 315.43 cells.
The next component considered - the danger of jeopardizing the
viability of the cells through addition of toxic medium or reagents -
necessitated a series of tests for evaluating toxicity. These tests
indicated toxic batches of fetal calf serum. Also they ensured that
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each batch of enriched medium was functioning properly. The tests
for polyethylene glycol (PEG) investigated the toxic effect of various
concentrations and exposure times of PEG on myeloma cells in an attempt
to minimize the damage to the cells, but allowing exposure comparable
to that directed in the fusion protocols. Cells exposed to PEG become
quite fragile and must therefore be kept from overexposure. Following
exposure to PEG it was found essential that the cells be handled very
gently, allowing the membranes to regain their normal tenacity, over
the ensuing 24 hours.
The immunization schedule is considered to be of prime importance
for the production within the spleen of activated B cells - the favoured
partner in cell fusion - and for increasing the level of and specificity
of antibody production by these cells. Evaluation of the response of
the spleen cells after various lag times, was attempted using the
Jerne plaque assay. This assay was met with very limited success
when the immunizing cell was of human origin, yet when the immunizing
cell was the sheep RBC no such problems were encountered. The reason
for this phenomenon is not clear. An article later discovered in which
Cunningham51 investigated the response of various species of animal
in the Jerne plaque assay also shows the lack of response of human
RBC in the Jerne plaque assay. Because of the non-response of the
human RBC in this assay, I decided to be guided by the accepted
immunization schedules for fusion work, found in the literature.
Indications were that 4 days post I ° immunization favoured Ig M
production, and that 4 days post-2° or muLt.i.p l,e immunization favoured
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Ig G production. The production of Ig M, a stronger direct agglutinin,
was desired and therefore the schedule selected was a single immunization
4 days before fusion of the cells.
The choice of mouse strain to be used in cell fusion was initially
based on the response each strain exhibited in the Jerne plaque assay
using the SRBC (sheep red blood cells) as immunogen and as target cell.
Little difference in the three strains was exhibited in terms of
response in the Jerne plaque assay. Therefore other criteria were used
in the choice of mouse strain. A hybridoma cell colony once established
can be grown to large numbers inside the BALB/c mouse, as an ascites
tumor. The BALB/ c mouse is particularly well suited to this purpose 34
but immunosupression for ascites growth of foreign types of cells is
necessary. The myeloma cell used is of BALB/c origin. If the second
parental cell of the hybridoma is also of BALB/c origin, no immuno-
suppression is needed to grow the hybridoma colony as the ascites tumor
in a BALB/c mouse. Although the ascites tumor growth of the hybridoma
was not planned for this investigation, the ability of the hybridomas
produced in this study to be easily adapted for ascites growth was
considered worthwhile for possible future studies. Therefore the
BALB/c strain of mouse was chosen for the fusion partner.
In many fusion experiments the use of ouabain appeared to prevent
the development of hybrid clones. Ouabain is used to kill off unfused
spleen cells. Al though some of these cells occasionally develop into
fibroblasts, this problem didn I t arise in these experiments and spleen
cells died off within several days of fusion. In the early stages of
hybridoma colony formation low cell density can prevent growth of cells
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in vitro. A feeder effect can be provided by many types of cells to
overcome this deficiency. The growth supportive effect of macrophages
has been successfully used in cloning under limiting dilution conditions
in liquid culture as well as for soft agar cloning50, 52,53 Thymus cells
and erythrocytes5 4, 55 h a ve also been used to provide a feeder effect in
cloning hybridoma cells. In my experiments it appears that in cultures
untreated with ouabain extra assistance in terms of a feeder effect
was provided by the surviving spleen cells during the first few days
after fusion. The critical period when few hybrid cells have developed
was therefore overcome and cloning efficiency increased in these cultures.
Direct agglutination of the immunogen, the human erythrocyte,
provides a simple test for determining if the culture supernatant
contains an appreciable amount of antibody specific for the human
erythrocyte surface, presumably secreted by the hybridoma colony.
Hybridomas which secrete antibody not specific for the immunogen arise
if the parental B cell was not activated by antigens on the human
erthrocyte surface. Inhibition of the antiglobulin test provides a
method for determining wells in which there is specific or non specific
antibody production by the hybridoma colonies. This test is capable of
detecting small amounts of immunoglobulin and can therefore be used to
indicate wells in which specific antibody production by hybridomas is
low and might otherwise be missed by direct agglutination. Any wells
which contain immunoglobulin by the inhibition test were tested by
direct agglutination for the specific antibody. In case antibody
production in these wells was a bit low due to hybridoma colonies
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being small or slow in becoming established, they were retested by
direct agglutination several days later. This insured that colonies
of hybridoma cells established within 24 days of fusion producing
antibody directed at Lmmuni.z i.nq human erythrocyte would be detected.
Of the 152 colonies of hybridoma cells, it was found that 82
secreted Lmmunoq Lobu.I i.n , These results agree well with work by
Milstein 's group28 in which Lmmunoq LobuLi.n production by viable hybrids
occurred in approximately 50 % of the hybrids. Of the 82 bybridomas
which secrete antibody only four were capable of agglutinating the human
erythrocyte. The Lmmunoqen , the human erythrocyte has many surface
molecules many of which could be the target for the Lmmune response
exhibited by the Lmmun.ize d mouse but in most species Lmmune response
appears to be preferential to certain antigens. High baokqrounds to
ABO antigens exists in the mouse, therefore to obtain antibody response
to other antigens, more extensive fusion experiments would be required.
In recent experiments by Mosmann et a1 56 cell fusion using the spleen
cells of a mouse Lmmun.i.zed with type A human erythrocytes was carried
out. Of a total of 74 hybrids that produced antibody to human
erythrocytes 53 were specific for the A blood group. In fusions by
this group a high response to both A and B antigens was fOW1d. This
strong preference for a particular determinant can only be revealed
by using the appropriate .immunoqen ,
In my experiments antigens present on the surface of the Lmmuni.z i.nq
cells were D,c,c,e,N,s,K,k,Leb,Fya,Fyb,Jkb,Kpb. The absence of A and B
antigens prevents the same strong preferential response exhibited in
the above mentioned fusion experiments. Antibodies produced by the
-86-
four hybridomas which agglutinate the immunizing erthrocytes also
agglutinate all cells of the panel of 87 humans indicating the likelihood
that the target antigen is common to most human RBC. It is possible that
if a larger number of cell donors are tested a rare one may be found
which is not agglutinated by one or other of the monoclonal antibodies.
Considering the preferential response to the antigens of the ABO system,
a response to the H antigen of this system is likely but would be
revealed only by testing for agglutination of the rare cells of the
Bombay phenotype which are lacking in A, Band H antigens. If the
antibodies which agglutinate all cells of the panel do not agglutinate
Bombay cells, the antibody is specific for the H antigen. As such a
test was not performed, the conclusions reached is that the anti-human
antibodies are directed at antigens common to must human erythrocytes.
In these experiments an allelic response was not demonstrated by
any of the four human erythrocyte agglutinating antibodies . The likelihood
of finding antibodies with allelic specificities would be increased if
additional fusion experiments were undertaken. A small percentage of human
erythrocyte agglutinating antibodies produced by resulting hybridomas
would be expected to display allelic specificity, but this would
necessitate more extensive fusion experiments not within the scope of
this study. Another approach could also increase the chance of
identifying allelic specificities: The use of a more extensive panel
of cells could be employed in which allelic forms of all known public
human erthrocyte antigens appear. With the small number of specific
anti-human antibodies resulting from my fusion experiments the lack of
an allelic response is not unexpected.
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CONCLUSION
The cell fusion technique was thoroughly investigated and is
currently being employed in this laboratory. Through the experiments
four bybridoma colonies were established and grown for several weeks
in tissue culture. Their products were analysed. It is evident from
these experiments that even when the basic techniques have been mastered,
the desired product of the hybridomas, namely antibodies with particular
allotypic specificity are still going to be difficult to obtain.
The yield of hybridomas increased dramatically when monitoring
of the cell viability was employed. In the interest of increasing
this yield still further it is felt that other aspects of the pre-
fusion considerations are worthy of refinement. That is the
immunization schedule and also the time between the immunization
and day of fusion. The schedules used in these studies can be
examined to determine variations which yield the highest numbers of
hybridomas. Even when the frequency of desirable hybrids is low,
rapid screening for specific antibody production would allow large
numbers of hybridomas to be practically handled. Such rapid screening
techniques include direct and indirect agglutination of the target
cells. Indirect agglutination using anti-mouse globulin has the
advantage of increased sensitivity over direct agglutination tests
and can still be carried out quickly on a large scale. It is felt
that it would be wise to discontinue the antiglobulin inhibition test
previously employed as this test is time consuming and superfluous
where direct and indirect agglutination would serve to locate those
clones secreting useful antibodies.
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Another aspect of the lymphocyte hybridoma study is worth
investigating. The use of the poly-L-lysine bound monolayer preparations
of erythrocytes bearing appropriately bound antigen was tried but not
pursued in these experiments. Selection of appropriate spleen cells
using this approach should increase the percentage of hybridomas
secreting the desired specificity of antibody. In continuing hybridoma
experiments it would be wise to use pre-selection procedures such as
this. A different approach to pre-selection which also should improve
the success of obtaining functional hybridomas includes rosetting
methods with appropriate antigens attached to sheep erythrocytes .
Preselection of cells used in conj unction with fusion methods for
small numbers of cells42 is in my opinion the best direction for
continuing experimentation , and would likely result in a larger
percentage of , the hybridomas secreting antibody wi t h a l lotypic
specificity.
An increasing number of laboratories are using monoclonal anti-
bodies in research and for various biomedical applications. As the
lymphocyte hybridoma techniques become widespread more complete data
on optimal conditions for growth , fusion and cloning of cells , are
being compiled. Applications of monoclonal antibodies are rapidly
expanding and hold great promise in biomedical fields. Up to now
continuous growth of human myeloma cells in vitro has remained a
formidable problem. Success in this area of lymphocyte cultures would
certainly open the way for obtaining human lymphocyte hybridomas
producing human monoclonal antibodies - which may well revolutionize
the clinical applications of monoclonal antibodies.
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